TickerFacts.

Kalaris Therapeutics, Inc. (KLRS): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$38.37M
Year ended 2025-12-31
-$41.02M
Trailing 12 months to 2026-06-30
2019-12-31: -$20.16M2020-12-31: -$60.81M2021-12-31: -$106.32M2022-12-31: -$142.05M2023-12-31: -$124.45M2024-12-31: -$20.67M2025-12-31: -$38.37M-$38.37M
2019-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31-$38.37Mn/m2026-03-17, From 2025-01-01
2024-12-31-$20.67Mn/m2026-03-17, From 2024-01-01
2023-12-31-$124.45Mn/m2025-03-07, From 2023-01-01
2022-12-31-$142.05Mn/m2024-03-15, From 2022-01-01
2021-12-31-$106.32Mn/m2023-02-15, From 2021-01-01
2020-12-31-$60.81Mn/m2022-02-10, From 2020-01-01
2019-12-31-$20.16Mn/a2021-02-12, From 2019-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Kalaris Therapeutics, Inc. (KLRS)2025-12-31-$38.37Mn/m
Acumen Pharmaceuticals, Inc. (ABOS)2025-12-31-$115.54Mn/m
Candel Therapeutics, Inc. (CADL)2025-12-31-$38.31Mn/m
Humacyte, Inc. (HUMA)2025-12-31-$105.04Mn/m
Zura Bio Ltd (ZURA)2025-12-31-$64.81Mn/m
Pelthos Therapeutics Inc. (PTHS)2025-12-31-$22.59Mn/m
Artiva Biotherapeutics, Inc. (ARTV)2025-12-31-$76.75Mn/m
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31-$18.92Mn/m
Palisade Bio, Inc. (PALI)2025-12-31-$10.85Mn/m

Compare KLRS, ABOS, CADL, HUMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗